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Abstract
Background: Meta-analysis of two randomised controlled trials in severe sepsis performed with
recombinant human activated protein C may provide further insight as to the therapeutic utility of
targeting the clotting cascade in this syndrome.
Methods: In search for relevant studies published, two randomized clinical trials were found
eligible.
Results: The studies, PROWESS and ADDRESS, enrolled a total of 4329 patients with risk ratio
(RR) and 95% confidence interval (CI) data for effect on 28-day mortality relative to control
treatment of 0.92 (0.83–1.02) suggesting that recombinant human activated protein C is not
beneficial in severe sepsis. In PROWESS, 873 of 1690 patients presented with low risk, and 2315
of 2639 patients in ADDRESS as defined by APACHE II score < 25. In this low-risk stratum, no
effect of recombinant human activated protein C administration on 28-day mortality was observed.
This observation appears to be consistent and homogenous. Heterogeneity between the two
studies, however, was seen in patients with APACHE II score ≥ 25 in whom recombinant activated
protein C was effective in PROWESS (n = 817; RR 0.71, CI 0.59–0.85) whereas a tendency toward
harm was present in ADDRESS (n = 324; RR 1.21, CI 0.85–1.74). Even though the overall treatment
effect in this high-risk population was still in favour of treatment with recombinant activated protein
C (n = 1141; RR 0.80, CI 0.68–0.94), the observed heterogeneity suggests that the efficacy of
recombinant human activated protein C is not robust. Not unlikely, the adverse tendency observed
could have become significant with higher statistical power would ADDRESS not have been
terminated prematurely.
Conclusion: This meta-analysis, therefore, raises doubts about the clinical usefulness of
recombinant activated protein C in patients with severe sepsis and an APACHE II score ≥ 25 which
can only be resolved by another properly designed clinical trial.
Background
Although coagulation abnormalities may partly underlie
the physiologic derangements of the sepsis syndrome,
anticoagulant therapies have produced mixed results on
survival in clinical studies. According to a recent meta-
analysis, anticoagulants as adjuvant therapy do not
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with a significant risk of bleeding complications [1]. To
the extent that their treatment effect is dependent upon
disease severity, the safety and efficacy of these agents may
be enhanced by refinement in techniques of clinical strat-
ification [2-4].
Recombinant human activated protein C (rhAPC) was
approved for use in severely septic patients based on the
results of the phase III PROWESS trial [5]. However, con-
cerns were raised regarding rhAPC's inconsistent effects,
incomplete understanding of its mechanism of action,
and its safety in particular subgroups [2]. Approval was
contingent among others upon agreement on post-
approval clinical trials [6]. In the meanwhile, one addi-
tonal large-scale randomised controlled clinical trial has
been completed, the ADDRESS study [7]. A new warning
has been added to the prescribing information for rhAPC
based upon exploratory analysis of the ADDRESS clinical
trial database [8,9]. Because a significant portion of
patients included in ADDRESS met inclusion and exclu-
sion criteria of the PROWESS subgroup of patients for
whom the current prescription labelling was given, we
hypothesized that a meta-analysis of the two clinical trials
of rhAPC in sepsis may provide further insight as to the
therapeutic utility of targeting the clotting cascade in this
syndrome with rhAPC.
Methods
Approval of rhAPC was based on the PROWESS phase III
trial [5]. Additional data on 28-day all-cause mortality
and safety among adult patients with severe sepsis who
were treated with rhAPC are available from the ENHANCE
prospective, single-arm, multicenter clinical trial (only the
US data of the trial have been published so far, [10]), and
from the ADDRESS study. The single-arm ENHANCE
study could enter meta-analysis only if historical controls
would be used which does, however, not fulfil criteria
usually applied in such type of analysis. Therefore, this
analysis will focus on two studies only, i.e. PROWESS and
ADRESS. Data from the PROWESS study are available
from its original publication and additional material pro-
vided for the registration process of the FDA. Data from
the ADDRESS have not yet been published in detail.
The primary objective of the ADDRESS trial was to dem-
onstrate that rhAPC can reduce mortality at 28 days in
adult patients with severe sepsis who have a lower risk of
death, compared to placebo and conventional care. It
originally planned to investigate the effectiveness of
rhAPC in 11,000 adult severe sepsis patients who have a
lower risk of death (APACHE score > 25; less than 2 organ
failure). The trial was terminated prematurely because of
futility to reach the primary study goal. The trial's data
were presented at the annual meeting of the European
Society of Intensive Care Medicine 2004 [7].
As approval of rhAPC is restricted to patients with severe
sepsis and a high risk of death, focus of this re-analysis
was on patient disease severity strata with APACHE II
score < 25 and those with ≥25. Cochran-Mantel-Haenszel
tests stratifying for study or for disease severity were per-
formed together with the corresponding risk ratios (RR)
and 95% confidence intervals (CI) for effect of rhAPC on
28 day mortality. For comparison pooled analyses and
analyses of individual studies were performed by Fishers
exact test. The homogeneity of treatment effects between
strata or between studies was assessed with the Breslow-
Day test.
Results and discussion
PROWESS and ADDRESS investigated the therapeutic
effects of rhAPC against placebo in patients with severe
sepsis early in their disease and at a dose of 24 µg/kg/hr
for a total infusion duration of 96 hours. Collectively, the
studies enrolled 4329 patients (PROWESS: 1690, and
ADDRESS: 2639). The RR (95% CI) for effect on 28-day
mortality of rhAPC, relative to control treatment, was 0.92
(0.83–1.02) with a nominal p-value of 0.095 (Cochran-
Mantel-Haenszel test). Observed heterogeneity between
the two studies (Breslow-Day test, p = 0.01) suggest possi-
ble differences in treatment effects of rhAPC which may
be due mainly to the higher frequency of low risk patients
in ADDRESS.
In PROWESS, 48.3% (817 of 1690) of patients presented
with APACHE II score ≥ 25 whereas in ADDRESS 12.3%
(324 of 2639) were in this group (Tab. 1). In these
patients with APACHE II score ≥ 25 inhomogeneity was
observed (Breslow-Day test, p = 0.005); whereas in
PROWESS, a treatment effect in favour of rhAPC was seen,
a tendency toward harm was present in ADDRESS. The
observed lack of homogeneity for the treatment effect
with rhAPC in the two trials raises doubt regarding the
robustness and the generalizability of the result. The over-
all effect in this patient group with higher risk remains
beneficial for rhAPC. Possibly the difference between the
two studies' results is due to differences in study design
with a higher number of patients of this stratum in
PROWESS than in ADDRESS. Another cause may lie in
rhAPC's efficacy itself which has not been uniformly sup-
ported given the limitations of PROWESS [2].
In PROWESS, 51.7% (873 of 1690) of patients presented
with APACHE II score < 25 whereas in ADDRESS 87.7%
(2315 of 2639) were in this group. In the low risk stratum
no effect of rhAPC administration neither in favour nor
against intervention was observed (Tab. 2). ThisPage 2 of 4
(page number not for citation purposes)
BMC Emergency Medicine 2005, 5:7 http://www.biomedcentral.com/1471-227X/5/7observation appears to be consistent and homogenous
(Breslow-Day test, p = 0.8).
Results of this meta-analysis are interesting, firstly as they
confirm in a large patient population the lack of efficacy
of rhAPC in low-risk severe sepsis, and secondly suggest
that beneficial treatment effects in high-risk patients may
also not be so robust because patients with APACHE II
score ≥ 25 did not derive benefit in ADDRESS. The adverse
tendency observed could probably have become signifi-
cant with higher statistical power would ADDRESS not
have been terminated prematurely. Even though specula-
tive, this might be an important aspect derived from this
analysis with consequences for the clinical use or rhAPC.
The Phase II trial testing the regimen of rhAPC applied in
PROWESS and ADDRESS was small with 131 patients
with severe sepsis only that were studied at 4 different
doses and for two different infusion periods [12]. Rele-
vance of the findings from this study in context of the
present analysis, however, is low because of patient char-
acteristics. The predominant portion of patients had sin-
gle (60%) or two-organ (33%) failure and the APACHE II
score was low (mean ± SD, 17.3 ± 5.8). As this was almost
exclusively a low risk patient population with a lack of
data available on patients with APACHE II > 25, and due
to the different dose levels which makes the study popu-
lation even smaller, the Phase II study was not included in
the current analysis.
Because of post-approval study obligations for the US
American Food and Drug Association (FDA), Eli Lilly
recently had to add a warning to the label of rhAPC
(Xigris) [8]: "Among the small number of patients
enrolled in PROWESS with single organ dysfunction and
recent surgery (surgery within 30 days prior to study treat-
ment), all-cause mortality was numerically higher in the
Xigris group (28-day: 10/49; in-hospital: 14/48) com-
pared to the placebo group (28-day: 8/49; in-hospital: 8/
47). In a preliminary analysis of the subset of patients
with single organ dysfunction and recent surgery from a
separate, randomized, placebo-controlled study
(ADDRESS) of septic patients at lower risk of death
(APACHE II score <25 or single sepsis-induced organ fail-
ure at any APACHE II score), all-cause mortality was also
higher in the Xigris group (28-day: 67/323; in-hospital:
76/325) compared to the placebo group (28-day: 44/313;
in-hospital: 62/314). Patients with single organ dysfunc-
tion and recent surgery may not be at high risk of death
irrespective of APACHE II score and therefore may not be
among the indicated population. Xigris should be used in
these patients only after careful consideration of the risks
and benefits."
The European Agency for the Evaluation of Medicinal
Products (EMEA) also tightened the Xigris label for the
European Union including the recommendation that the
product only be used in high-risk patients, mainly in situ-
ations when therapy can be started within 24 hours of the
Table 1: Meta-analysis of effects of rhAPC on 28-day mortality in patients with severe sepsis and APACHE II score of ≥25 at study 
entry
Clinical Trial N rhAPC Control RR 95% CI p-Value
PROWESS 817 30.9 43.7 0.71 0.59 – 0.85 0.0002 1
ADDRESS 324 29.7 24.5 1.21 0.85 – 1.74 0.32 1
Total 1141 30.6 38.3 0.80 0.68 – 0.94 0.007 1,2,3
1 two-sided Fishers exact test
2 Cochran-Mantel-Haenszel test, p = 0.006
3 Breslow-Day test homogeneity, p = 0.005.
Table 2: Meta-analysis of effects of rhAPC on 28-day mortality in patients with severe sepsis and APACHE II score of <25 at study 
entry
Clinical Trial N rhAPC Control RR 95% CI p-Value
PROWESS 873 18.8 19.0 0.99 0.75–1.30 1.0 1
ADDRESS 2315 16.8 16.0 1.05 0.88–1.27 0.6 1
Total 3188 17.3 16.8 1.03 0.89–1.20 0.7 1,2,3
1 two-sided Fishers exact test
2 Cochran-Mantel-Haenszel test, p = 0.007
3 Breslow-Day test homogeneity, p = 0.007.Page 3 of 4
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onset of organ failure and that it should only be used by
experienced doctors in institutions skilled in the care of
patients with severe sepsis [9].
A primary therapeutic target of rhAPC is the prevention of
thrombin formation. The conflicting effects pf rhAPC in
PROWESS and ADDRESS in higher risk patients raises
concerns regarding original FDA and EMEA analyses sug-
gesting that risk of death alters the effects of rhAPC in sep-
sis. This questions also arises in the context of other
antithrombotic agents such as antithrombin III and tissue
factor pathway inhibitor which can only be answered in
prospectivem randomized controlled trials.
Conclusion
This meta-analysis confirms that rhAPC is not effective in
low-risk patients with severe sepsis, and it suggests that
also beneficial treatment effects in high-risk patients may
not be robust. It supports recent restrictive regulatory deci-
sions in the European Union and the United States of
America on Xigris and is in line with most recent develop-
ments from clinical trials, namely that Lilly has had to
stop early a pediatric clinical study of Xigris after interim
results showed that it was ineffective and might pose a
safety risk in this population [11]. This meta-analysis
raises doubts about the clinical usefulness of recombinant
activated protein C in patients with severe sepsis and an
APACHE II score ≥ 25 which can only be resolved by
another properly designed clinical trial.
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